It also blocks various cells signaling pathways, such as Raf-1 proto-oncogene, B-Raf proto-oncogene, and kinase activity in the MAPK/ERK signaling pathways to inhibit tumor progression and angiogenesis and promotes tumor cell apoptosis.[5] Sorafenib was the first oral small-molecule tyrosine kinase inhibitor to be approved as a first-line treatment for advanced HCC. This evidence concerns the gene BRAF and neoplasm.